1-(4-碘苄基)哌啶 | 651022-26-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(4-碘苄基)哌啶
• 英文名称: 4-(N-piperidinylmethyl)iodobenzene
• 英文别名: 1-(4-iodo-benzyl)-piperidine；1-(4-Iodobenzyl)piperidine；1-[(4-iodophenyl)methyl]piperidine
• CAS: 651022-26-3
• 化学式: C₁₂H₁₆IN
• 分子量: 301.17
• InChiKey: UBTQOFNYBSZILI-UHFFFAOYSA-N

物化性质

• 沸点：
  306.9±17.0 °C(Predicted)
• 密度：
  1.521±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-(4-碘苄基)哌啶 、 3,17β-bis(hydroxy)-7α-(6-hexynyl)-estra-1,3,5(10)-triene 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以54%的产率得到3,17β-bis(hydroxy)-7α-[6-(4-piperidin-1-ylmethyl-phenyl)-hex-5-ynyl]-estra-1,3,5(10)-triene
  参考文献：
  名称：

  Synthesis of Novel Estrogen Receptor Antagonists Using Metal-Catalyzed Coupling Reactions and Characterization of Their Biological Activity

  摘要：

  Estrogen receptor (ER) antagonists are valuable in the treatment of ER-positive human breast cancer. In this study, we designed and synthesized nine new derivatives of 17 beta-estradiol (E-2) with a bulky side chain attached to its C-7 alpha position, and determined their ER antagonistic activity using in vitro bioassays. Four of the derivatives showed a strong inhibition of ER alpha transactivation activity in a luciferase reporter assay and blocked ER alpha interactions with coactivators. Similarly, these derivatives also strongly inhibited the growth of the ER alpha-positive human breast cancer cells. Computational docking analysis was conducted to model the interaction of these antagonists with the human ER alpha and showed that they could tightly bind to the ER alpha in a manner similar to that of ICI-182,780, a pure ER antagonist. These results provide an example that attachment of a bulky side chain to the C-7 alpha position of E-2 can produce ER antagonists with ER affinity comparable to that of ICI-182, 780.

  DOI：

  10.1021/jm3013773
• 作为产物：
  描述：

  piperidin-1-yl-[4-(iodo)phenyl]methanethione 在 五羰基溴化锰(I) 、 氢气 、 三乙胺 、 copper(I) bromide 作用下， 100.0 ℃ 、3.0 MPa 条件下， 反应 1.0h， 以93%的产率得到1-(4-碘苄基)哌啶
  参考文献：
  名称：

  一种催化硫代酰胺衍生物氢化脱硫的方法

  摘要：

  本发明提出的是一种催化硫代酰胺衍生物氢化脱硫的方法，通过向聚四氟乙烯内衬反应管中依次加入五羰基溴化锰催化剂、反应底物硫代酰胺衍生物、Lewis酸、溶剂和碱，将反应管放置于高压釜内，充入氢气进行催化氢化反应后冷却至室温，放出气体，用乙酸乙酯冲洗反应管，过硅胶小短柱并旋干，经柱色谱提纯后得到目标产物。本发明通过利用毒性较低、化学选择性和生物相容性较好的一价锰作为催化剂催化硫代酰胺衍生物的氢化脱硫，底物范围较广，胺的产率高，具有较大的药物合成应用价值。

  公开号：

  CN113061121B

文献信息

• [EN] PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS<br/>[FR] INHIBITEURS DE PHOSPHODIESTERASE 4 COMPRENANT DES ANALOGUES DE DIPHENYLAMINE ET D'ANILINE N-SUBSTITUES
  申请人：MEMORY PHARM CORP

  公开号：WO2004009552A1

  公开（公告）日：2004-01-29

  PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula (I): wherein R1, R2 R 3 and R4 are as defined herein.

  PDE4抑制作用是通过新型化合物实现的，例如N-取代苯胺和二苯胺类似物。本发明的化合物为公式(I)：其中R1，R2，R3和R4如本文所述定义。
• Zinc-Catalyzed Chemoselective Reduction of Tertiary and Secondary Amides to Amines
  作者：Shoubhik Das、Daniele Addis、Kathrin Junge、Matthias Beller

  DOI：10.1002/chem.201101143

  日期：2011.10.17

  procedures for the catalytic hydrosilylation of secondary and tertiary amides under mild conditions have been developed. In the presence of inexpensive zinc catalysts, tertiary amides are easily reduced by applying monosilanes. Key to success for the reduction of the secondary amides is the use of zinc triflate and disilanes with dual SiH moieties. The presented hydrosilylations proceed with excellent

  已经开发了在温和条件下催化仲和叔酰胺氢化硅烷化的通用且方便的方法。在廉价的锌催化剂存在下，通过应用甲硅烷很容易还原叔酰胺。还原仲酰胺成功的关键是使用三氟甲磺酸锌和具有双SiH部分的乙硅烷。在敏感的酯，硝基，偶氮，腈，烯烃和其他官能团的存在下，提出的加氢甲硅烷基化反应具有优异的化学选择性，因此使该方法对有机合成具有吸引力。
• Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
  申请人：Schumacher A. Richard

  公开号：US20050119225A1

  公开（公告）日：2005-06-02

  PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R 1 , R 2 , R 3 and R 4 are as defined herein.

  PDE4抑制是通过新型化合物实现的，例如，N-取代苯胺和二苯胺类似物。本发明的化合物属于公式I：其中R1，R2，R3和R4如本文所定义。
• Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
  申请人：Lehmann-Lintz Thorsten

  公开号：US20050267093A1

  公开（公告）日：2005-12-01

  Compounds of formula (I) wherein A, B, b, W, X, Y, Z, R 1 , R 2 , and R 3 have the meanings given in claim 1, pharmaceutical compositions these compounds, and methods of preventing or treating metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes using these compounds.

  化合物的公式（I），其中A，B，b，W，X，Y，Z，R1，R2和R3具有权利要求1所给出的含义，制备这些化合物的药物组合物，以及使用这些化合物预防或治疗代谢紊乱和/或进食障碍，特别是肥胖症，暴食症，厌食症，暴饮暴食和糖尿病的方法。
• PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS
  申请人：SCHUMACHER Richard A.

  公开号：US20090048255A1

  公开（公告）日：2009-02-19

  PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R 1 , R 2 , R 3 and R 4 are as defined herein.

  PDE4抑制是通过新型化合物实现的，例如N-取代苯胺和二苯胺类似物。本发明的化合物属于I式：其中R1、R2、R3和R4的定义如本文所述。